
|Videos|September 20, 2017
Dr. West Discusses Results of the Phase III FLAURA Study in NSCLC
Author(s)H. Jack West, MD
H. Jack West, MD, medical oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the results of the phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non–small cell lung cancer (NSCLC).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
2
FDA Approves Novel Interchangeable Biosimilar for Pertuzumab in HER2+ Breast Cancer
3
Rethinking Advanced Prostate Cancer: Surprising Finds from a Landmark Study
4
How Resting Immune Cells Could Be the Key to Fighting Prostate Cancer
5








































